Background Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …

Immune checkpoint inhibitors (ICIs), which target CTLA-4 or PD-(L) 1 molecules, have
shown impressive therapeutic results. Durable responses, however, are only observed in a …

Simple Summary Immune checkpoint inhibitors (ICIs) have revolutionized treatment of
advanced melanoma and survival of melanoma patients has radically improved since …

Background Immune checkpoint inhibition (ICI) with anti-CTLA-4 and/or anti-PD-1
antibodies is standard treatment for metastatic melanoma. Anti-PD-1 (pembrolizumab …

Introduction: Advanced melanoma has recently been transformed by the advent of immune
checkpoint inhibitors. These agents have altered the prognosis of this disease from a …

Immune checkpoint blockade (ICB) therapy has achieved remarkable clinical benefit in
melanoma. However, our understanding of biomarkers that predict response to ICB …

The treatment and prognosis of metastatic melanoma has changed substantially since the
advent of novel immune checkpoint inhibitors (ICI), agents that enhance the anti-tumor …

Introduction Immune checkpoint inhibitor (ICI) based immunotherapy is dramatically
changing the management of many types of cancers including melanoma. In this …

Simple Summary Immunotherapy has revolutionized the therapeutic landscape of
melanoma. However, the absence of clinically validated predictive biomarkers is one of the …

Abstract Background Immune checkpoint inhibitors (ICIs) have changed the clinical
management of melanoma. However, not all patients respond, and current biomarkers …